The University of Maryland Marlene and Stewart Greenebaum Comprehensive Cancer Center has been awarded a $3 million National Cancer Institute Career Development Award to support early-career oncology researchers focused on improving cancer outcomes for patients from diverse backgrounds. The program, called Advancing Oncology Research C...
The NRG-LU005 trial found that immunotherapy atezolizumab did not improve survival for patients with limited-stage small cell lung cancer when added to chemoradiation. Twice-daily radiation therapy, however, was associated with improved survival in this population.
The Alliance for Clinical Trials in Oncology is spotlighting new trials for colorectal cancer in March, focusing on early detection methods and treatments for treatment delays and loss of appetite. The trials aim to improve patient outcomes, with several enrolling patients with newly diagnosed colon or rectal cancer.
Peter WT Pisters, MD, receives the prestigious Charles M. Balch, MD, Distinguished Service Award for his substantial contributions to surgical oncology through service, research, and leadership. He is recognized as a renowned cancer surgeon, researcher, and hospital administrator.
The Alliance for Clinical Trials in Oncology will host a webinar highlighting recent clinical advances in breast cancer, multiple myeloma, and leukemia. Researchers will present key findings from ASH and SABCS meetings, impacting treatment outcomes.
Approximately 40 cancer patients will receive LMP744 for five consecutive days, with biological analyses conducted on brain tissues before and after treatment. If results are favorable, treatment will continue for 12 cycles to evaluate parameters such as progression-free survival and overall survival.
The integration of OMOP Oncology into Mayo Clinic Platform enables faster analysis of complex cancer data, unlocking deeper insights and accelerating research. This expansion supports the development of next-generation therapies for patients worldwide.
A Phase II study presents significant overall survival benefits for women with platinum-resistant ovarian cancer treated with elenagen plus gemcitabine. Longer exposure to elenagen correlates with longer survival after treatment discontinuation, suggesting a fundamentally different therapeutic approach.
Halle Zhang joins Insilico Medicine to lead global clinical development strategy for the company's oncology portfolio. She brings over 20 years of experience in oncology clinical development and a track record of advancing therapies through registrational trials.
The ACHILLES project trains researchers in experimental haematological oncology, developing advanced models, analysis tools, and therapeutic targets for leukaemia and lymphoma. The project aims to bridge basic and preclinical research with clinical practice, improving survival rates and accessibility to innovative treatments.
Researchers identified a targetable driver of brain metastases in inflammatory breast cancer, promoting tumor invasion and triggering brain inflammation via the CXCR2 signaling pathway. Targeting sEcad or the CXCR2 pathway may treat or prevent brain metastasis.
Sujuan Ba, CEO of the National Foundation for Cancer Research, has been recognized as one of OncoDaily's 100 Most Influential CEOs in Oncology in 2025. Under her leadership, NFCR has strengthened its role as a strategic accelerator of cancer research, supporting innovative science and fostering cross-sector collaboration.
NRG Oncology has added several new leadership members to its Brain Tumor, Breast Cancer, Genitourinary Cancer, Lung Cancer, Medical Oncology, and Translational Science committees. Deborah K. Armstrong will lead the NRG Medical Oncology Committee, while Daniel P. Cahill will serve as Surgical Oncology Vice Chair of the NRG Brain Tumor C...
Insilico Medicine collaborates with Servier to develop novel therapeutics in oncology through AI-driven platform Pharma.AI. The partnership is focused on identifying promising targets and generating molecular structures with desired properties.
The American Society for Radiation Oncology (ASTRO) has rebranded its research foundation as Speed of Light – The ASTRO Foundation, marking a renewed focus on advancing research and improving patient care. The new initiative aims to strengthen research collaborations and investments to drive progress in radiation oncology.
A new study by researchers from the Germans Trias i Pujol Research Institute provides a comparative analysis of the impact of BRAF gene mutations in melanoma and colorectal cancer. The review highlights molecular, cellular, and tumour microenvironment factors that explain the therapeutic dichotomy between the two tumour types.
Researchers at UT Health Sciences Center have developed an AI-enhanced platform called ENRICH, which leverages advanced analytics with community-based human support to reduce treatment interruptions and improve cancer outcomes. The program identifies patients at highest risk for interruption and deploys targeted support resources.
Renuka Iyer, a leading oncologist with extensive experience in cancer care and research, has been appointed as the new Chief Medical Officer of the National Comprehensive Cancer Network. She will oversee the development of evidence-based guidelines for cancer prevention and treatment.
The ESMO Immuno-Oncology Congress 2025 will discuss key developments in immuno-oncology, including combined approaches, AI in cancer therapy, and innovative strategies across various cancers. The congress aims to advance the field of immunotherapy and improve patient outcomes.
A new study by University of Texas M. D. Anderson Cancer Center researchers has identified a myeloid mimicry pathway that drives tumor hyper progression following immunotherapy in renal medullary carcinoma, highlighting specific targets for overcoming treatment resistance.
Zanidatamab demonstrated significant efficacy in patients with HER2-positive biliary tract cancer, achieving response rates of up to 51.6% and improving symptoms such as pain levels. The trial's results support the emerging role of zanidatamab as a treatment paradigm for this rare and aggressive cancer.
Andres M. Álvarez-Pinzón joins NRG Developmental Therapeutics Committee, bringing expertise in oncology clinical trials and translational medicine. Ronald Chen becomes Chair of the NRG Patient Centered Outcomes Research Committee, focusing on improving cancer outcomes through clinical trials and patient-reported outcomes.
Linda Bulone, a Queens Cancer Center Oncology nurse, received the 2025 Alliance Clinical Research Professionals Research Integrity Service Excellence (CRP RISE) Award. She has significantly increased clinical trial participation, expanded early screening efforts, and supported reductions in late-stage diagnoses.
The American Society for Radiation Oncology (ASTRO) has published its first clinical guideline on radiation therapy for gastric cancer. The guidelines provide evidence-based recommendations for the role of radiation therapy in multidisciplinary care, including patient selection, integration with systemic therapy and treatment delivery.
The ESMO Congress on Artificial Intelligence and Digital Oncology features a diverse range of presentations on multimodal AI for clinical decision support, AI-based biomarkers for precision oncology, and digital health in practice. The congress also explores ethics, regulation, and patient perspectives.
Medical imaging foundation models revolutionize cancer precision medicine by integrating multimodal data, AI algorithms, and large language models. They enhance diagnostic accuracy and clinical interpretability, facilitating personalized therapy and intelligent clinical decision support.
The new clinical cancer research center will support lung and genitourinary cancers, serving as a central hub for seven VA medical centers. The grant aims to improve access to precision oncology trials and patient care for veterans diagnosed at later stages.
This study analyzed the temporal evolution of three LLMs in oncology, finding that subjective questions degrade faster over time than objective queries. The results highlight the need for ongoing performance monitoring and strategies to integrate up-to-date clinical data for safe and reliable AI deployment in cancer care.
Recent research in pathological foundation models has demonstrated robust representation learning capabilities and generalization performance. These models enable multi-task transfer with minimal data, significantly enhancing clinical utility and generalizability.
Dr. Lovly brings nearly two decades of experience in clinical care, research and academic leadership to her new role, shaping the modern landscape of lung cancer care. Her expertise in precision medicine will be instrumental in accelerating progress for patients with lung cancer across the country.
Scientists at St. Jude Children's Research Hospital developed a new approach to safely reduce therapy in children with medulloblastoma, a pediatric brain tumor. The analysis of almost 900 patients identified four actionable treatment recommendation groups from low to high intensity.
The DEFEND study aims to assess whether virtual exercise sessions can be successfully delivered to patients with cancer receiving chemotherapy. Researchers will evaluate the impact on physical function, fatigue, and disability.
Dr. Vinai Gondi joins the NRG Brain Tumor Committee, Dr. Bridget Koontz leads the Ancillary Projects Committee, and Dr. Priya Rastogi chairs the Breast Cancer Committee, with new leadership starting March 1, 2026.
Ochsner MD Anderson Cancer Center has seven locations recertified for quality cancer care, demonstrating a commitment to comprehensive holistic care. The QOPI Certification Program recognizes these locations for meeting national standards and objectives.
The Mays Cancer Center stands among the nation's leading institutions recognized for excellence in cancer care and research. It is one of only four NCI-designated Cancer Centers in Texas, offering specialized programs and delivering comprehensive, multidisciplinary care supported by clinical research.
The University of Texas MD Anderson Cancer Center has honored two outstanding nurses, Kimberly Vanderhorst and Terri Lynn Dunn, with the 2025 Brown Foundation Award for Excellence in Oncology Nursing. The award recognizes exceptional patient care and a commitment to excellence in clinical practice.
The ESMO Guidance on the Use of Large Language Models in Clinical Practice (ELCAP) provides a structured set of recommendations for safely adopting AI language models in oncology. The guidance emphasizes the importance of human oversight, transparent tools, and continuously monitored systems to ensure trust in AI-driven cancer care.
Patients receiving mRNA-based COVID vaccines showed improved survival rates and responses to immunotherapy, especially in 'cold' tumors with low PD-L1 expression. The study suggests that these vaccines can reprogram immune responses against cancer, potentially improving outcomes for patients with treatment-resistant disease.
The ESMO Congress 2025 will cover key topics including precision oncology, antibody-drug conjugates in breast cancer, dose optimisation strategies, new treatment modalities for melanoma, and immunotherapy-based approaches across various cancer settings. Promising Phase-3 studies on ADCs in bladder and lung cancer are also expected.
The WIN Symposium, featuring oncology experts, aims to accelerate the translation of research into clinical practice through keynote lectures and networking opportunities. The event is part of the Advancing Precision Medicine (APM) Annual Conference 2025.
A novel gene therapy targets and kills cancer cells infected with the Kaposi's sarcoma-associated herpesvirus (KSHV), while leaving healthy cells unharmed. The treatment uses a harmless virus to deliver a genetic 'Trojan horse' into infected cells, converting an anti-herpesvirus drug into a cancer-killing agent.
Researchers identified specific ways to address religion and spirituality during radiation therapy, highlighting their importance in patient coping mechanisms. The study found that nearly all patients considered spiritual history questions helpful, especially those related to coping with stress.
A large phase III trial found that stereotactic body radiation therapy (SBRT) preserves quality of life, with fewer declines in bowel and urinary functioning. However, SBRT does not outperform standard radiation therapy for disease-free survival, with higher rates of biochemical failure and rising PSA after treatment.
Cancer rehabilitation programs in Australia have more than doubled since 2015, yet many survivors face barriers to accessing exercise-based care. According to a national survey, nearly half of respondents cite lack of funding as a challenge to program sustainability.
Researchers at Fox Chase Cancer Center found adaptive radiation therapy can reduce radiation to healthy tissue by 21% while delivering higher doses to tumors. The study offers new hope for patients with previously untreatable cancers.
The NRG-GU005 clinical study shows that SBRT significantly improves bowel health-related quality of life in patients with localized immediate risk prostate cancer. However, no significant improvement was seen for urinary HRQOL, and SBRT was not superior to IMRT in terms of distant-free survival.
A retrospective study found that radiation therapy controlled ventricular tachycardia with fewer complications than standard catheter ablation. Radiation therapy was similarly effective in controlling arrhythmia and showed lower serious side effects, especially in the early time window.
Dr. Amar Kishan has been recognized for his groundbreaking research on radiation treatments for genitourinary system cancers. He is the recipient of the 2025 Steven A. Leibel Memorial Award, presented by ASTRO and ABR Foundation.
A new randomized study validates a predictive gene expression test that identifies patients with recurrent prostate cancer who will benefit from adding hormone therapy to radiation. The test, PAM50, groups tumors into molecular subtypes and predicts treatment outcomes.
Researchers from UCLA presented findings on targeted radioactive therapy, new SBRT approaches and advances in MRI- and 5DCT-guided imaging. The LUNAR clinical trial looked at adding a targeted therapy before ablative radiotherapy for men with recurrent prostate cancer.
The University of Cincinnati Cancer Center researchers are presenting several studies on radiation oncology, including the evaluation of efficacy and safety of proton re-irradiation in head and neck cancers, significant variation in oropharyngeal cancer treatment approaches, and severe toxicity rare following liver cancer ablative radi...
The NRG Oncology PREDICT-RT study has completed patient accrual, evaluating intensified and de-intensified concurrent radiation regimens for high-risk prostate cancer patients. The study aims to improve quality of life and outcomes by tailoring treatments based on genomic risk scores.
The Alliance for Clinical Trials in Oncology will host a public webinar showcasing key findings from the 2025 ASCO Annual Meeting. Researchers will discuss latest information on colorectal, squamous cell, and renal cell cancers.
The American Society for Radiation Oncology, American Society of Clinical Oncology, and Society of Surgical Oncology jointly published a guideline outlining when post-mastectomy radiation therapy (PMRT) is appropriate based on new evidence. PMRT reduces cancer recurrence risk in patients with node-positive disease or high-risk features.
Experts weighed in on the current state of artificial intelligence (AI) in cancer care, noting both its potential for improving efficiency and its challenges. Many expressed excitement over AI's possibilities for helping support an overburdened oncology workforce and accelerating the pursuit of new cures.
A study published in Oncoscience found that over 60% of oncology healthcare professionals in Morocco showed signs of severe burnout, with emotional exhaustion being the key factor. The study highlights the need for urgent institutional changes to support healthcare workers and improve work environments.
The Molecular Analysis for Precision Oncology Congress 2025 (MAP) brings together leading experts to explore the latest cancer research advances. Key topics include AI-integrated diagnostics and therapy, as well as immunotherapy and emerging developments in aging and cellular senescence.
The Ellen Siow Professorship aims to advance education and research in neuro-oncology, specifically glioblastoma. This will drive the development of innovative programmes and interventions, fostering progress that benefits people in Singapore and beyond.
Dr. Catheryn Yashar, a renowned radiation oncologist, has been appointed president-elect of the American Society for Radiation Oncology (ASTRO). She will champion innovative radiation therapies and advance health policy reform to improve cancer care outcomes.
Julie Bauman, MD, MPH, is appointed Deputy Chair of NRG's NCORP Research Base, while Ryan Burri, MD, becomes the VA-MTF Subcommittee Vice Chair. These appointments aim to enhance cancer research and treatment through multi-center clinical studies.